Skip to main content

Dr. Thomas L. Headstream, M.D.

Internal Medicine (Internal Medicine Physician)

  • Medicare participating

At a glance

Years since graduation
47
In the NPI registry since
2005
Medicare patients seen, 2024
1,916

Licensed in Texas since 1982, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1979Medical school: University of Texas Southwestern Medical School at Dallas
  • 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Internal Medicine Physician primary
    TX license G2148 (first issued 1982; active)

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Internal Medicine per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
1,916
Services billed
27,650
Patients’ average age
76
Most frequent Medicare services, 2023
ServiceTimesPatients
Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge2,221537
Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha)2,176525
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count2,0071,051
Insertion of needle into vein for collection of blood sample1,633873
Blood test, comprehensive group of blood chemicals1,375802
Blood test, basic group of blood chemicals (calcium, total)994494
Blood test, thyroid stimulating hormone (tsh)946647
Blood test, lipids (cholesterol and triglycerides)837616
Ldl cholesterol level823607
Manual urinalysis test with examination using microscope, automated817529

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 1 companies reported 1 payments worth $23.82 in total to this clinician.

By company
AbbVie Inc.$23.82
By type
Food and Beverage$23.82

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Texas →

Industry-funded research

Named as a principal investigator on 8 industry-funded studies in 2025, from 4 companies. The companies reported $365,311 in research payments for these studies, mostly to the institutions running them.

  • NB (Contrave) Cardiovascular Outcomes Trial
    Currax Pharmaceuticals LLC
  • A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age
    ModernaTX, Inc. · Completed · NCT06634797
  • A Phase IIb Randomized Double blind Placebo controlled and Open label Active Comparator Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus
    AstraZeneca Pharmaceuticals LP
  • A phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure…
    AstraZeneca Pharmaceuticals LP
  • A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate …
    AstraZeneca Pharmaceuticals LP
  • Post marketing commitment study to assess clinical efficacy & safety of current JN.1-based formulation with focus on lower-risk adults (50-64 years) to inform benefit-risk profile (PMC2)
    ModernaTX, Inc.
  • A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Povetacicept in Adults With Immunoglobulin A Nephropathy (RAINIER)
    Vertex Pharmaceuticals Incorporated
  • Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630
    AstraZeneca Pharmaceuticals LP

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Internal Medicine clinicians in Abilene

Sources

NPI registry (CMS NPPES, November 2026; record last updated August 7, 2019), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1053300863. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.